Selling pressure pushes GSK stock lower in today's trading

Traders Union
All News
Financial News
GSK slides 2.07% today to GBX2033.00

Highlights

GSK repurchased 965,671 shares at GBX 2,081.15, raising treasury holdings to 6.45% of voting rights as part of its buyback program.
Despite ongoing capital management actions, GSK's shares remain under notable selling pressure in current trading.
Technical signals indicate persistent short-term bearish sentiment, but major indicators suggest over 80% probability of upward price movement toward the GBX 2,068 resistance range.

Buyback increases treasury holdings as selling pressure persists

GSK announced the repurchase of 965,671 of its own ordinary shares on April 22, 2026, as part of its ongoing share buyback program. The shares were acquired at a volume-weighted average price of GBX 2,081.15 per share, increasing treasury holdings to 261,378,286, or about 6.45% of total voting rights. This transaction is part of the company's broader capital management strategy, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees GSK under persistent selling pressure despite its recent share buyback activity. He notes that the stock consistently trades below short- and medium-term moving averages, which signals clear technical weakness. The buyback has not halted the negative sentiment, and overhead resistance at GBX 2,068.00 limits recovery prospects. Kharitonov remains cautious on further upside, warning that a break below GBX 2,013.78 may accelerate losses. "Until buyers reclaim key technical levels, I expect downward bias to persist for GSK."

Viktoras Karapetjanc, expert at Traders Union, is constructive on GSK's outlook. He highlights the company's robust buyback strategy as a sign of confident capital management and long-term value focus. With shares above the 200-day average and all major weekly indicators pointing to a likely rebound, the bullish structure remains intact. Karapetjanc expects upward momentum if GBX 2,068.00 is reclaimed. "Investors should view recent consolidation as a setup for further growth in GSK."

Mid-term bearish trend as long-term support remains intact

GSK is trading well below its 20-day (GBX 2,111.11) and 50-day (GBX 2,106.04) moving averages, but remains comfortably above the 200-day level (GBX 1,775.47), indicating the short- and medium-term trend favors sellers, while the long-term structure is still supportive. The nearest dynamic support and resistance are flagged at the Ichimoku Kijun level (GBX 2,054.14) and the 50-day moving average, respectively.

Earlier, analysts noted that GSK’s ongoing share buybacks and expanding R&D initiatives were supportive for the company’s long-term outlook despite mixed short-term technical momentum. This latest pullback sharpens the focus on whether dynamic support near GBX 2,013.78 will hold, as a sustained recovery above resistance would signal renewed bullish momentum in the days ahead.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.